Hematopoietic stem cells RNA silencing guide

HSCs present unique biological barriers that make them one of the most challenging primary cell types for genetic manipulation:

Quiescent state and low metabolic activity

More than 90% of LT-HSCs exist in deep G0 quiescence with minimal metabolic activity, a state essential for preserving their self-renewal capacity. This dormancy makes them resistant to lipofection, which depends on active endocytosis. Electroporation in quiescent cells causes irreversible membrane damage due to inability to repair pores. Forcing HSCs into cycle with cytokines to enable transfection paradoxically triggers differentiation, destroying the very stemness researchers aim to study. This leaves a hard choice: maintain quiescence, where transfection can fail, or activate the cells and lose HSC identity.

Extreme sensitivity to ex vivo manipulation

HSCs begin losing self-renewal capacity within hours of removal from their bone marrow niche. Within 48-72 hours of culture, even under optimal conditions with cytokine cocktails (SCF, TPO, FLT3L), HSCs progressively differentiate into committed progenitors, losing long-term repopulating ability. Transfection stress accelerates this process: lipofection triggers stress response pathways that induce differentiation. The mechanical stress of electroporation activates p53 and causes HSCs to exit quiescence permanently. The window is narrow, and a method that stresses the cells can cost stemness before knockdown is achieved.

Limited cell numbers

HSCs are exceptionally rare, comprising only 0.01-0.1% of total bone marrow cells. A typical cord blood unit yields only 10,000-50,000 CD34+CD38- HSCs, while adult bone marrow aspiration provides 100,000-500,000 HSCs. Unlike other cell types, HSCs cannot be expanded without differentiation; every division reduces self-renewal capacity. This scarcity leaves little material for optimization and calls for methods that work with small cell inputs. Conventional transfection is often optimized on far larger cell numbers, which can put that optimization out of reach in an HSC study.

Loss of engraftment potential

The ability to home to and engraft in the bone marrow niche is the defining functional property of HSCs. Conventional transfection can significantly disrupt this ability. Electroporation can downregulate CXCR4, the chemokine receptor essential for bone marrow homing, with the degree of reduction depending on pulse conditions, buffer composition, and cytokine supplementation. Lipofection may alter expression of adhesion molecules (CD44, VLA-4, L-selectin) required for HSC-niche interactions. Even HSCs that survive transfection often show reduced performance in competitive repopulation assays, the gold standard for HSC function. This makes conventional methods challenging for transplantation studies, the primary clinical application of HSC research.

Rapid differentiation ex vivo

HSCs spontaneously differentiate in culture even under optimized conditions. Within 72 hours, the CD34+CD38- LT-HSC population decreases by 60-80%, replaced by CD34+CD38+ committed progenitors. This differentiation is accelerated by transfection stress, with lipofection causing loss of the CD38- fraction. Cytokine-driven expansion protocols that enhance transfection efficiency paradoxically reduce stemness: each division decreases self-renewal capacity exponentially. The addition of expansion compounds (small molecule HSC expansion compound, aryl hydrocarbon receptor antagonist) can slow but not prevent this differentiation, creating a race against time for genetic manipulation.

Heterogeneity and subset complexity

The HSC compartment contains multiple functionally distinct subpopulations with varying self-renewal capacities and lineage biases. LT-HSCs, ST-HSCs, MPPs, and lineage-biased HSCs each show different transfection susceptibilities and stress responses. Myeloid-biased HSCs are more resistant to transfection than lymphoid-biased HSCs. This heterogeneity means bulk transfection preferentially affects certain subsets, skewing experimental outcomes. Single-cell analyses reveal that conventional transfection creates artificial selection pressures, enriching for stress-resistant but functionally altered HSC subclones.

Method comparison

Transfection-free RNA silencing for HSC research

Why AUMsilence™ sdASOs™ suit HSCs

Key benefits

• Works without cell activation Does not require forcing cell cycle entry that triggers differentiation. Compatible with quiescent HSC states.
• Efficient gene knockdown Typically achieves 70-95% knockdown in CD34+CD38- HSCs. Does not require transfection reagents that can compromise cell viability or phenotype.
• Homing markers Electroporation can downregulate CXCR4, the chemokine receptor essential for bone marrow homing. No electric pulse is applied, and CXCR4 and the adhesion molecules are read on the treated cells.
• Compatible with limited cell numbers Suitable for experiments with small HSC numbers. No complex optimization required for rare cell populations.
• HSC phenotype The CD34+CD38- phenotype and multilineage differentiation are read on the treated cells, by flow cytometry and a CFU assay.
• Rapid protocol AUMsilence sdASOs are added to the culture medium. Results in 24-72 hours without lengthy viral production.

Cell types and applications

• CD34+ human HSPCs from cord blood or mobilized peripheral blood
• Mouse bone marrow LSK cells and LT-HSCs
• Ex vivo HSC expansion studies with small molecule HSC expansion compound/aryl hydrocarbon receptor antagonist
• Pre-transplantation functional studies
• Clonal hematopoiesis and CHIP modeling
• Leukemia stem cell research
• HSC aging and exhaustion studies
• Lineage bias and differentiation control
• Niche interaction and homing studies

• AUMsilence™ sdASO™

Alternative products

• AUMantagomir™ sdASO™ When to use: For microRNA inhibition in HSCs. Target miR-126-3p (HSC quiescence) or miR-29a-3p (HSC self-renewal). miR-125 names a family, miR-125a and miR-125b, so an inhibitor is made against one member and one arm.
• AUMlnc™ sdASO™ When to use: For nuclear lncRNAs regulating HSC fate. Target HOTAIR, XIST, or other chromatin-associated lncRNAs.

Cell-type-optimized protocols for human CD34+ HSPCs, mouse bone marrow HSCs, and expanded HSCs. No transfection reagent is required.

Quick start protocol (all HSC types)

1. 01Culture HSCs in serum-free medium with cytokines (SCF, TPO, FLT3L)
2. 02Add AUMsilence™ sdASO™ directly to culture medium (typical range: 5-20 μM depending on target)
3. 03Incubate 48-72 hours at 37°C, 5% CO₂ in hypoxic conditions (5% O₂) if possible
4. 04Validate knockdown by qRT-PCR and flow cytometry while monitoring CD34/CD38 expression

Cell-type-specific protocols

Human CD34+ HSPCs from cord blood

Used for transplantation studies in animal models

1. 01

   Step 1: CD34+ cell isolation

   Thaw cryopreserved cord blood units or process fresh cord blood. Perform density gradient separation to isolate mononuclear cells. Use immunomagnetic CD34+ selection kit (positive selection) to achieve >95% purity. Count viable cells with 7-AAD exclusion.
   
   Materials: Density gradient medium, CD34 MicroBead Kit, automated magnetic cell separator or manual separation columns
   
   Note: Work quickly to minimize time outside of culture. Expect 0.1-0.5% CD34+ cells from cord blood MNCs.
   
   Timing: Day 0 (2-3 hours)
2. 02

   Step 2: HSC culture setup

   Culture CD34+ cells at 2-5 × 10⁵ cells/mL in serum-free expansion medium optimized for hematopoietic cells. Supplement with human cytokines: SCF (100 ng/mL), TPO (100 ng/mL), FLT3L (100 ng/mL). Optional: add small molecule HSC expansion compound (35 nM) or aryl hydrocarbon receptor antagonist (0.75 μM) for expansion while maintaining stemness.
   
   Materials: Serum-free expansion medium, recombinant human SCF/TPO/FLT3L, low-adhesion plates
   
   Note: Use low-adhesion plates to prevent differentiation. Maintain at 5% O₂ (hypoxia) if possible to preserve stemness.
   
   Timing: Day 0
3. 03

   Step 3: AUMsilence sdASO treatment

   Add AUMsilence sdASO directly to HSC culture. Typical concentration range is 5-20 μM depending on target stability and expression level. No media change required. For 500 μL culture at 10 μM, add 5 μL of 1 mM stock. Mix gently by pipetting.
   
   Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)
   
   Note: AUMsilence sdASOs are taken up by endocytosis. Optimize concentration based on target gene.
   
   Timing: Day 0 or Day 1
4. 04

   Step 4: Incubation

   Incubate at 37°C, 5% CO₂, preferably at 5% O₂ (hypoxic conditions) for 48-72 hours. Do not change medium during this period to maintain ASO concentration.
   
   Materials: Hypoxic incubator or tri-gas incubator
   
   Note: Monitor cell morphology daily. Healthy HSCs appear small and round without differentiation.
   
   Timing: Days 0-3
5. 05

   Step 5: Validation and phenotyping

   Harvest cells by gentle pipetting. Perform flow cytometry with HSC markers: CD34, CD38, CD45RA, CD90, CD49f. Analyze target knockdown by qRT-PCR. Assess viability with 7-AAD. Optional: perform CFU assay to verify multipotency.
   
   Materials: Flow cytometry antibodies, RNA extraction kit, methylcellulose for CFU
   
   Note: Monitor CD34+CD38- frequency to assess stemness preservation. Knockdown efficiency: 70-95% knockdown.
   
   Timing: Day 2-3

Mouse bone marrow LSK cells

For in vivo transplantation and mechanistic studies

1. 01

   Step 1: Bone marrow harvest

   Sacrifice mice (8-12 weeks old) and harvest femurs and tibias. Flush bone marrow with IMDM + 2% FBS using 27G needle. Create single-cell suspension by pipetting. Perform red blood cell lysis if needed.
   
   Materials: IMDM medium, 27G needles, 5 mL syringes, RBC lysis buffer
   
   Note: Work on ice to maintain viability. Pool marrow from 2-4 mice for sufficient HSC yield.
   
   Timing: Day 0
2. 02

   Step 2: Lineage depletion and FACS sorting

   Perform lineage depletion using biotinylated lineage antibody cocktail (CD3, B220, Gr-1, Mac-1, Ter119) and streptavidin magnetic beads. Stain Lin- cells with Sca1-PE, cKit-APC, and optionally CD150-Pacific Blue, CD48-FITC. Sort LSK (Lin-Sca1+cKit+) cells or LT-HSCs (LSK CD150+CD48-).
   
   Materials: Lineage depletion kit, flow cytometry antibodies, cell sorter
   
   Note: LSK cells are ~0.1% of bone marrow. CD150+CD48- LT-HSCs are ~0.01%.
   
   Timing: Day 0
3. 03

   Step 3: Mouse HSC culture and ASO treatment

   Culture sorted HSCs at 5 × 10⁴ cells/mL in serum-free expansion medium with mouse cytokines: mSCF (50 ng/mL), mTPO (50 ng/mL), mIL-3 (10 ng/mL), mIL-6 (10 ng/mL). Add AUMsilence sdASO directly (typical range: 5-20 μM depending on target).
   
   Materials: Serum-free expansion medium, recombinant mouse cytokines, AUMsilence sdASO
   
   Note: Mouse HSCs are more fragile than human; handle gently. Use U-bottom 96-well plates for small cell numbers.
   
   Timing: Day 0
4. 04

   Step 4: Competitive transplantation setup

   After 48-72h ASO treatment, mix treated HSCs (CD45.2) with competitor bone marrow cells (CD45.1) at 1:1 or 1:10 ratio. Transplant into lethally irradiated recipients (9.5 Gy split dose). Monitor chimerism at 4, 8, 16 weeks after transplant.
   
   Materials: CD45.1/CD45.2 congenic mice, irradiator, flow cytometry reagents
   
   Note: Successful knockdown should not impair engraftment unless targeting HSC-essential genes.
   
   Timing: Day 2-3 for transplant

Ex vivo expanded HSCs

For increased cell numbers while attempting to maintain stemness

1. 01

   Step 1: HSC expansion culture

   Start with freshly isolated CD34+ cells at 5 × 10⁴ cells/mL. Use animal component-free expansion medium with expansion cocktail: SCF (100 ng/mL), TPO (100 ng/mL), FLT3L (100 ng/mL), IL-6 (20 ng/mL). Add expansion compounds: small molecule HSC expansion compound (35 nM) or aryl hydrocarbon receptor antagonist (0.75 μM) or both.
   
   Materials: Animal component-free expansion medium, cytokines, small molecule HSC expansion compound/aryl hydrocarbon receptor antagonist expansion compounds
   
   Note: Small molecule HSC expansion compound maintains CD34+CD38- phenotype better than aryl hydrocarbon receptor antagonist alone.
   
   Timing: Days 0-7
2. 02

   Step 2: AUMsilence sdASO addition during expansion

   At day 3-5 of expansion when cells have increased 5-10 fold, add AUMsilence sdASO. Can be added directly to expansion culture without medium change.
   
   Materials: AUMsilence sdASO
   
   Note: Expanding cells may require higher ASO concentrations due to dilution from proliferation.
   
   Timing: Day 3-5
3. 03

   Step 3: Monitoring stemness during knockdown

   Every 48h, analyze small aliquot by flow cytometry: CD34, CD38, CD45RA, CD90. Track the CD34+CD38- frequency against the phenotype the cells started with.
   
   Materials: Flow cytometry antibodies
   
   Note: If CD38- population drops below 30%, cells are differentiating excessively.
   
   Timing: Days 3-10

Pre-transplantation knockdown

For functional studies requiring in vivo engraftment

1. 01

   Step 1: Timing optimization

   Treat HSCs with AUMsilence sdASO 48-72h before planned transplantation. This allows knockdown while minimizing culture time that can affect engraftment.
   
   Materials: Standard HSC culture setup with AUMsilence sdASO
   
   Note: Do not exceed 96h total culture time as engraftment drops significantly.
   
   Timing: 48-72h before transplant
2. 02

   Step 2: Pre-transplant validation

   Reserve 10-20% of cells for knockdown validation. Perform qRT-PCR for target gene and flow cytometry for CD34/CD38/CXCR4 expression.
   
   Materials: Validation reagents
   
   Note: Confirm that CXCR4 expression is maintained (>80% positive) for proper homing.
   
   Timing: Day of transplant
3. 03

   Step 3: Transplantation protocol

   Resuspend knockdown HSCs in PBS + 2% FBS at 1 × 10⁶ cells/mL. Inject 2-5 × 10⁵ CD34+ cells per mouse (immunodeficient strain) via tail vein. For competitive repopulation, mix with carrier/competitor cells.
   
   Materials: Immunodeficient mice (NSG or other severely immunocompromised strain), injection supplies
   
   Note: Include untreated and non-targeting ASO control groups.
   
   Timing: Day 2-3 post-ASO

Essential controls

• Untreated HSCs: Baseline for stemness markers and engraftment potential
  Culture identically but without ASO addition
• Non-targeting control ASO: Control for ASO-related effects on HSC function
  Use at same concentration as experimental ASO
• Vehicle control for expansion: When using small molecule HSC expansion compound/aryl hydrocarbon receptor antagonist, include DMSO vehicle control
  Critical for expansion studies to separate compound effects

Optimization strategies for HSCs

Troubleshooting

Loss of CD34+CD38- population

• Reduce culture time to 48h
• Use hypoxic conditions (5% O₂)
• Add small molecule HSC expansion compound (35 nM) to maintain stemness
• Reduce cytokine concentrations by 50%
• Work with freshly isolated cells, not previously cultured

Poor engraftment after knockdown

• Verify CXCR4 expression maintained >80%
• Limit total culture to 72h
• Transplant immediately after knockdown validation
• Increase cell dose to compensate
• Check if target gene involved in adhesion/homing pathways

Low knockdown efficiency (<60%)

• Increase ASO within 5-20 μM
• Extend incubation to 72h
• Pre-stimulate HSCs for 24h before ASO (sacrifices some stemness)
• Test multiple ASO sequences targeting different regions
• Consider combination with cell cycle entry (with caution)

Variable results across donors

• Standardize source (use only cord blood or only mobilized)
• Confirm >95% CD34+ purity post-isolation
• Test n≥3 donors for statistical power
• Report donor characteristics in publications

Validation covers the target transcript and protein, the HSC phenotype, colony formation, quiescence and engraftment. Where the target itself governs stemness or homing, a change in these readouts is the expected phenotype.

Flow cytometry immunophenotyping

Colony-forming unit (CFU) assays

Competitive repopulation assays

Single-cell approaches

Cell cycle analysis

qRT-PCR validation

Critical controls for HSC studies

• Freshly isolated HSCs
  Purpose: Baseline for all stemness markers
  Analyze immediately post-isolation to establish starting phenotype and gene expression.
• Cultured untreated HSCs
  Purpose: Account for culture-induced changes
  Culture identically but without ASO. Monitors baseline differentiation in culture.
• Non-targeting control ASO
  Purpose: ASO-specific effects on HSC function
  Critical control: use at same concentration to verify effects are target-specific.
• Positive control knockdown
  Purpose: Verify ASO uptake and activity
  Use housekeeping gene ASO (e.g., GAPDH, ACTB) to confirm knockdown capability in your HSC system.
• Competition controls
  Purpose: For transplantation studies
  Include untreated competitor cells to assess relative fitness.

Best practices

• Always monitor CD34+CD38- frequency as primary stemness readout
• Validate knockdown at both mRNA (qPCR) and protein (flow/Western) levels
• Perform functional validation (CFU or transplant) for critical experiments
• Use hypoxic culture conditions (5% O₂) when possible
• Limit total culture time to preserve engraftment potential
• Include multiple donors (n≥3) for human studies due to variability
• Report both knockdown efficiency and functional outcomes